Respiratory and lower limb muscle function in interstitial lung disease

Chronic Respiratory Disease

Volumn 13, Issue 2, 2016, Pages 162-172

  Panagiotou, Marios ^a   Polychronopoulos, Vlasis ^b   Strange, Charlie ^c  

^a GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

^b IASO GENERAL HOSPITAL   (Greece)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Interstitial lung disease; muscle dysfunction; respiratory muscles; risk factors; skeletal muscle

Indexed keywords

ARTICLE; BREATHING MUSCLE; DISEASE ASSOCIATION; DYSPNEA; FORCED EXPIRATORY VOLUME; HIGH RISK PATIENT; HUMAN; HYPOXIA; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LEG MUSCLE; MUSCLE DISEASE; MUSCLE DYSFUNCTION; MUSCLE FATIGUE; MUSCLE FUNCTION; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYOSITIS; PRIORITY JOURNAL; RISK ASSESSMENT; LOWER LIMB; PATHOPHYSIOLOGY; QUADRICEPS FEMORIS MUSCLE; RISK FACTOR; SKELETAL MUSCLE;

DYSPNEA; HUMANS; LOWER EXTREMITY; LUNG DISEASES, INTERSTITIAL; MUSCLE FATIGUE; MUSCLE, SKELETAL; QUADRICEPS MUSCLE; RESPIRATORY MUSCLES; RISK FACTORS;

EID: 84966658388     PISSN: 14799723     EISSN: 14799731     Source Type: Journal    
DOI: 10.1177/1479972315626014     Document Type: Article

References (63)

1. Interstitial lung disease. In: Gibson GJ, Loddenkemper R, Sibille Y, et al. (eds) European Lung White Book. 2nd ed. Sheffield: European Respiratory Society, 2013, pp. 256-269.
2. Nishiyama O, Taniguchi H, Kondoh Y, et al. Quadriceps weakness is related to exercise capacity in idiopathic pulmonary fibrosis. Chest 2005; 127: 2028-2033.
3. Chang JA, Curtis JR, Patrick DL, et al. Assessment of health-related quality of life in patients with interstitial lung disease. Chest 1999; 116: 1175-1182.
4. Caminati A, Bianchi A, Cassandro R, et al. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med 2009; 103: 117-123.
5. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
6. Hansen JE, Wasserman K,. Pathophysiology of activity limitation in patients with interstitial lung disease. Chest 1996; 109: 1566-1576.
7. Holland AE,. Exercise limitation in interstitial lung disease-mechanisms, significance and therapeutic options. Chron Respir Dis 2010; 7: 101-111.
8. O'Donnell DE, Chau LK, Webb KA,. Qualitative aspects of exertional dyspnea in patients with interstitial lung disease. J Appl Physiol (1985) 1998; 84: 2000-2009.
9. Verges S, Bachasson D, Wuyam B,. Effect of acute hypoxia on respiratory muscle fatigue in healthy humans. Respir Res 2010; 11: 109.
10. Katayama K, Amann M, Pegelow DF, et al. Effect of arterial oxygenation on quadriceps fatigability during isolated muscle exercise. Am J Physiol Regul Integr Comp Physiol 2007; 292: R1279-R1286.
11. Rahman I, Skwarska E, Henry M, et al. Systemic and pulmonary oxidative stress in idiopathic pulmonary fibrosis. Free Radic Biol Med 1999; 27: 60-68.
12. Bringardner BD, Baran CP, Eubank TD, et al. The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid Redox Signal 2008; 10: 287-301.
13. Liu RM,. Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis. Antioxid Redox Signal 2008; 10: 303-319.
14. Hiraiwa K, van Eeden SF., Nature and consequences of the systemic inflammatory response induced by lung inflammation. In: Ong KC, (ed) Lung Inflammation, http://intechopen.com/books/lung-inflammation/nature-and-consequences-of-the-systemic-inflammatory-response-induced-by-lung-inflammation (. 2014, accessed 18 July 2015).
15. Moylan JS, Reid MB,. Oxidative stress, chronic disease, and muscle wasting. Muscle Nerve 2007; 35: 411-429.
16. Oshima Y, Kuroda Y, Kunishige M, et al. Oxidative stress-associated mitochondrial dysfunction in corticosteroid-treated muscle cells. Muscle Nerve 2004; 30: 49-54.
17. Darmaun D, Matthews DE, Bier DM,. Physiological hypercortisolemia increases proteolysis, glutamine, and alanine production. Am J Physiol 1988; 255: E366-E373.
18. Decramer M, Lacquet LM, Fagard R, et al. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 1994; 150: 11-16.
19. Mitsui T, Azuma H, Nagasawa M, et al. Chronic corticosteroid administration causes mitochondrial dysfunction in skeletal muscle. J Neurol 2002; 249: 1004-1009.
20. Kozu R, Senjyu H, Jenkins SC, et al. Differences in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Respiration 2011; 81: 196-205.
21. Spruit MA, Thomeer MJ, Gosselink R, et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax 2005; 60: 32-38.
22. Wickerson L, Mathur S, Helm D, et al. Physical activity profile of lung transplant candidates with interstitial lung disease. J Cardiopulm Rehabil Prev 2013; 33: 106-112.
23. Nakayama M, Bando M, Araki K, et al. Physical activity in patients with idiopathic pulmonary fibrosis. Respirology 2015; 20: 640-646.
24. Jackman RW, Kandarian SC,. The molecular basis of skeletal muscle atrophy. Am J Physiol Cell Physiol 2004; 287: C834-C843.
25. Bodine SC,. Disuse-induced muscle wasting. Am J Physiol Cell Physiol 2013; 45: 2200-2208.
26. Li H, Malhotra S, Kumar A,. Nuclear factor-kappa B signaling in skeletal muscle atrophy. J Mol Med (Berl) 2008; 86: 1113-1126.
27. Maddocks M, Shrikrishna D, Vitoriano S, et al. Skeletal muscle adiposity is associated with physical activity, exercise capacity and fibre shift in COPD. Eur Respir J 2014; 44: 1188-1198.
28. Alakhras M, Decker PA, Nadrous HF, et al. Body mass index and mortality in patients with idiopathic pulmonary fibrosis. Chest 2007; 131: 1448-1453.
29. Kim JH, Lee JH, Ryu YJ, et al. Clinical predictors of survival in idiopathic pulmonary Fibrosis. Tuberc Respir Dis (Seoul) 2012; 73: 162-168.
30. Saunders J, Smith T,. Malnutrition: causes and consequences. Clin Med 2010; 10: 624-627.
31. Jeejeebhoy KN,. Muscle function and nutrition. Gut 1986; 27: 25-39.
32. Lopes J, Russell DM, Whitwell J, et al. Skeletal muscle function in malnutrition. Am J Clin Nutr 1982; 36: 602-610.
33. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A statement of the American Thoracic Society and European Respiratory Society. Am J Respir Crit Care Med 1999; 159: S1-S40.
34. De Troyer A, Yernault JC,. Inspiratory muscle force in normal subjects and patients with interstitial lung disease. Thorax 1980; 35: 92-100.
35. Laveneziana P,. Qualitative aspects of exertional dyspnea in patients with restrictive lung disease. Multidiscip Respir Med 2010; 5: 211-215.
36. Nishimura Y, Hida W, Taguchi O, et al. Respiratory muscle strength and gas exchange in neuromuscular diseases: comparison with chronic pulmonary emphysema and idiopathic pulmonary fibrosis. Tohoku J Exp Med 1989; 159: 57-68.
37. Garcia-Rio F, Pino JM, Ruiz A, et al. Accuracy of noninvasive estimates of respiratory muscle effort during spontaneous breathing in restrictive diseases. J Appl Physiol (1985) 2003; 95: 1542-1549.
38. Mendoza L, Gogali A, Shrikrishna D, et al. Quadriceps strength and endurance in fibrotic idiopathic interstitial pneumonia. Respirology 2014; 19: 138-143.
39. Watanabe F, Taniguchi H, Sakamoto K, et al. Quadriceps weakness contributes to exercise capacity in nonspecific interstitial pneumonia. Respir Med 2013; 107: 622-628.
40. Walterspacher S, Schlager D, Walker DJ, et al. Respiratory muscle function in interstitial lung disease. Eur Respir J 2013; 42: 211-219.
41. Gorini M, Spinelli A, Ginanni R, et al. Neural respiratory drive and neuromuscular coupling during CO2 rebreathing in patients with chronic interstitial lung disease. Chest 1989; 96: 824-830.
42. Martin JG, De Troyer A,. The behaviour of the abdominal muscles during inspiratory mechanical loading. Respir Physiol 1982; 50: 63-73.
43. Abraham KA, Feingold H, Fuller DD, et al. Respiratory-related activation of human abdominal muscles during exercise. J Physiol 2002; 541: 653-663.
44. Elia D, Kelly JL, Martolini D, et al. Respiratory muscle fatigue following exercise in patients with interstitial lung disease. Respiration 2013; 85: 220-227.
45. De Troyer A,. Cournand lecture: mechanical action of the abdominal muscles. Bull Eur Physiopathol Respir 1983; 19: 575-581.
46. Kyroussis D, Mills GH, Polkey MI, et al. Effect of maximum ventilation on abdominal muscle relaxation rate. Thorax 1996; 51: 510-515.
47. Polkey MI, Kyroussis D, Hamnegard CH, et al. Diaphragm performance during maximal voluntary ventilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 155: 642-648.
48. Polkey MI, Kyroussis D, Keilty SE, et al. Exhaustive treadmill exercise does not reduce twitch transdiaphragmatic pressure in patients with COPD. Am J Respir Crit Care Med 1995; 152: 959-964.
49. Sacco P, McIntyre DB, Jones DA,. Effects of length and stimulation frequency on fatigue of the human tibialis anterior muscle. J Appl Physiol (1985) 1994; 77: 1148-1154.
50. Baydur A, Alsalek M, Louie SG, et al. Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis. Chest 2001; 120: 102-108.
51. Romer LM, Polkey MI,. Exercise-induced respiratory muscle fatigue: implications for performance. J Appl Physiol (1985) 2008; 104: 879-888.
52. Costabel U,. Skeletal muscle weakness, fatigue and sarcoidosis. Thorax 2005; 60: 1-2.
53. Pringle CE, Dewar CL,. Respiratory muscle involvement in severe sarcoid myositis. Muscle Nerve 1997; 20: 379-381.
54. Dewberry RG, Schneider BF, Cale WF, et al. Sarcoid myopathy presenting with diaphragm weakness. Muscle Nerve 1993; 16: 832-835.
55. Baydur A, Pandya K, Sharma OP, et al. Control of ventilation, respiratory muscle strength, and granulomatous involvement of skeletal muscle in patients with sarcoidosis. Chest 1993; 103: 396-402.
56. Kabitz HJ, Lang F, Walterspacher S, et al. Impact of impaired inspiratory muscle strength on dyspnea and walking capacity in sarcoidosis. Chest 2006; 130: 1496-1502.
57. Brancaleone P, Perez T, Robin S, et al. Clinical impact of inspiratory muscle impairment in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 219-227.
58. Korenromp IH, Heijnen CJ, Vogels OJ, et al. Characterization of chronic fatigue in patients with sarcoidosis in clinical remission. Chest 2011; 140: 441-447.
59. Iliffe GD, Pettigrew NM,. Hypoventilatory respiratory failure in generalised scleroderma. BMJ 1983; 286: 337-338.
60. Russell DC, Maloney A, Muir AL,. Progressive generalized scleroderma: respiratory failure from primary chest wall involvement. Thorax 1981; 36: 219-220.
61. Kalluri M, Oddis CV,. Pulmonary manifestations of the idiopathic inflammatory myopathies. Clin Chest Med 2010; 31: 501-512.
62. Teixeira A, Cherin P, Demoule A, et al. Diaphragmatic dysfunction in patients with idiopathic inflammatory myopathies. Neuromuscul Disord 2005; 15: 32-39.
63. American Thoracic Society/European Respiratory S. ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med 2002; 166: 518-624.